CN102918038B - 新的多晶型物 - Google Patents

新的多晶型物 Download PDF

Info

Publication number
CN102918038B
CN102918038B CN201180026714.4A CN201180026714A CN102918038B CN 102918038 B CN102918038 B CN 102918038B CN 201180026714 A CN201180026714 A CN 201180026714A CN 102918038 B CN102918038 B CN 102918038B
Authority
CN
China
Prior art keywords
proline
methyl
tetrahydrochysene
aza
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180026714.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102918038A (zh
Inventor
约翰·亨里克·谢尔斯特伦
比约恩·埃里克·约翰松
托马斯·威廉森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vantia Ltd
Original Assignee
Vantia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia Ltd filed Critical Vantia Ltd
Publication of CN102918038A publication Critical patent/CN102918038A/zh
Application granted granted Critical
Publication of CN102918038B publication Critical patent/CN102918038B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
CN201180026714.4A 2010-04-01 2011-03-31 新的多晶型物 Expired - Fee Related CN102918038B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1005623.2A GB201005623D0 (en) 2010-04-01 2010-04-01 New polymorph
GB1005623.2 2010-04-01
US34704810P 2010-05-21 2010-05-21
US61/347,048 2010-05-21
PCT/GB2011/000500 WO2011121308A1 (en) 2010-04-01 2011-03-31 New polymorph

Publications (2)

Publication Number Publication Date
CN102918038A CN102918038A (zh) 2013-02-06
CN102918038B true CN102918038B (zh) 2015-09-09

Family

ID=42228830

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180026714.4A Expired - Fee Related CN102918038B (zh) 2010-04-01 2011-03-31 新的多晶型物

Country Status (20)

Country Link
US (1) US9079881B2 (cg-RX-API-DMAC7.html)
EP (1) EP2552910B1 (cg-RX-API-DMAC7.html)
JP (1) JP5802737B2 (cg-RX-API-DMAC7.html)
KR (1) KR101792621B1 (cg-RX-API-DMAC7.html)
CN (1) CN102918038B (cg-RX-API-DMAC7.html)
CA (1) CA2795109C (cg-RX-API-DMAC7.html)
DK (1) DK2552910T3 (cg-RX-API-DMAC7.html)
ES (1) ES2538085T3 (cg-RX-API-DMAC7.html)
GB (1) GB201005623D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20150513T1 (cg-RX-API-DMAC7.html)
HU (1) HUE026442T2 (cg-RX-API-DMAC7.html)
ME (1) ME02102B (cg-RX-API-DMAC7.html)
MX (1) MX2012011382A (cg-RX-API-DMAC7.html)
PL (1) PL2552910T3 (cg-RX-API-DMAC7.html)
PT (1) PT2552910E (cg-RX-API-DMAC7.html)
RS (1) RS53956B1 (cg-RX-API-DMAC7.html)
RU (1) RU2559633C2 (cg-RX-API-DMAC7.html)
SI (1) SI2552910T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201500107B (cg-RX-API-DMAC7.html)
WO (1) WO2011121308A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN103755707B (zh) * 2013-09-17 2015-11-18 天津药物研究院 利希普坦晶型ⅱ及其制备方法和用途
CN104059070B (zh) * 2013-09-17 2016-02-10 天津药物研究院有限公司 利希普坦晶型ⅰ及其制备方法和用途
CN103694240B (zh) * 2013-09-18 2015-11-18 天津药物研究院 利希普坦的溶剂合物及其制备方法和用途
CN104140429B (zh) * 2014-07-25 2015-11-18 天津药物研究院 利希普坦晶型ⅴ及其制备方法和用途
EP4616852A3 (en) 2015-07-22 2025-10-22 Anavex Life Sciences Corp. Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions
WO2020154581A1 (en) 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049682A1 (en) * 2000-01-05 2001-07-12 Ferring Bv Condensed azepines as vasopressin agonists
CN1462269A (zh) * 2000-06-26 2003-12-17 费林股份公司 稠合的氮杂䓬衍生物及其作为抗利尿剂的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW359669B (en) 1995-12-15 1999-06-01 Otsuka Pharma Co Ltd Benzazepine derivatives
ES2229523T3 (es) 1997-07-30 2005-04-16 Wyeth Agonistas triciclicos de la vasopresina.
IL133788A0 (en) 1997-07-30 2001-04-30 American Home Prod Tricyclic vasopressin agonists
WO2000046227A1 (en) 1999-02-04 2000-08-10 American Home Products Corporation Thienylbenzoylbenzazepines as vasopressin agonists
PT1149096E (pt) 1999-02-04 2003-03-31 Wyeth Corp N-oxidos de piridina triciclicos agonistas de vasopressina
WO2000046228A2 (en) 1999-02-04 2000-08-10 American Home Products Corporation Pyrrolobenzodiazepine carboxyamide vasopressin agonists
CN1339035A (zh) 1999-02-04 2002-03-06 美国家用产品公司 吡啶并苯并二吖庚因和吡啶并苯并氧杂吖庚因酰胺血管加压素激动剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049682A1 (en) * 2000-01-05 2001-07-12 Ferring Bv Condensed azepines as vasopressin agonists
CN1462269A (zh) * 2000-06-26 2003-12-17 费林股份公司 稠合的氮杂䓬衍生物及其作为抗利尿剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
New Benzylureas as a Novel Series of Potent, Nonpeptidic Vasopressin V2 Receptor Agonists;Christopher M. Yea,等;《J. Med. Chem.》;20081124;第51卷(第24期);第8124-8134页 *

Also Published As

Publication number Publication date
KR101792621B1 (ko) 2017-11-02
HUE026442T2 (en) 2016-06-28
RU2012146544A (ru) 2014-05-10
RU2559633C2 (ru) 2015-08-10
KR20130023218A (ko) 2013-03-07
CA2795109A1 (en) 2011-10-06
GB201005623D0 (en) 2010-05-19
JP2013523706A (ja) 2013-06-17
DK2552910T3 (en) 2015-04-07
ME02102B (me) 2015-10-20
CN102918038A (zh) 2013-02-06
PL2552910T3 (pl) 2015-07-31
CA2795109C (en) 2018-04-17
HRP20150513T1 (hr) 2015-06-05
SI2552910T1 (sl) 2015-06-30
SMT201500107B (it) 2015-07-09
MX2012011382A (es) 2013-01-29
US20140296213A1 (en) 2014-10-02
EP2552910A1 (en) 2013-02-06
EP2552910B1 (en) 2015-03-11
RS53956B1 (sr) 2015-08-31
US9079881B2 (en) 2015-07-14
WO2011121308A1 (en) 2011-10-06
ES2538085T3 (es) 2015-06-17
PT2552910E (pt) 2015-05-13
JP5802737B2 (ja) 2015-11-04

Similar Documents

Publication Publication Date Title
US9309201B2 (en) Process for preparating ivabradine hydrochloride form IV and methods of treatment of disease using ivabradine hydrochloride form IV
DK2552910T3 (en) New polymorph
JP2644234B2 (ja) 形態学的に均質型のチアゾール誘導体の製造方法
CN103237547B (zh) 结晶纳络醇-peg缀合物
JP2016509031A (ja) トレラグリプチンの固形形式及びその製造方法と用途
EP4541793A1 (en) Rupatifen fumarate crystal form c, and preparation method therefor and use thereof
CN109336881A (zh) 一种利伐沙班晶体
CN104341343A (zh) 贝曲西班的晶型及其制备方法和用途
US20080234286A1 (en) Stable amorphous imatinib mesylate and production process therefor
JP2007527924A (ja) 非晶質バルサルタンの製造方法
RU2594164C2 (ru) Способ получения 1-(2-метил-4-(2,3,4,5-тетрагидро-1-бензазепин-1-илкарбонил)бензилкарбамоил)-l-пролин-n,n-диметиламида
CN100422159C (zh) Bifeprunox甲磺酸盐的稳定的多晶型物
ZA200508640B (en) Crystal of benzimidazole derivative and process for producing the same
CN103804366A (zh) 一种拉呋替丁晶型化合物
US20080249149A1 (en) Crystalline Forms of Rizatriptan Benzoate
WO2008027419A2 (en) Tizanidine sulfate salt forms and methods of making and using the same
WO2007084761A1 (en) Maleate salt of tegaserod and crystalline forms thereof
KR20060116422A (ko) 용해도가 개선된 실로스타졸 복합체 조성물 및 그 제조방법
BR112022008769B1 (pt) Processo para a preparação de um citrato férrico (iii) de alta pureza
WO2006019835A1 (en) A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20200331

CF01 Termination of patent right due to non-payment of annual fee